Skip to main content

Market Overview

Tickers

Articles

Keywords

Search by keyword...
googlecse

Piper Jaffray Raises PT On Novavax To $4
Joe Young  
 
March 01, 2011 6:45am   Comments
Share:

Piper Jaffray has raised the price target on Novavax, Inc. (NASDAQ: NVAX) from $3 to $4 and maintains its Overweight rating.

© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

 

Related Articles (NVAX)

Novavax Ups Outlook, Eyes Stronger Nuvaxovid Sales
RFK Jr. Halts $500 Million In mRNA Vaccine Projects Backed By Pfizer, Moderna: 'We're Prioritizing Safer, Broader Strategies'
Earnings Scheduled For August 6, 2025
Novavax Stock Dips As Moderna's Woes Weigh On Vaccine Sector
Novavax Shares Promising Results For Bird Flu Vaccine, Tested In Primates
FDA Grants Complete Approval To Moderna's COVID-19 Vaccine For Children As Young As 6 Months
View Comments and Join the Discussion!

Posted-In: Novavax Piper JaffrayPrice Target Analyst Ratings

Latest Ratings

StockFirmActionPT
SEDGB of A SecuritiesMaintains411.0
PTLOPiper SandlerMaintains28.0
AOUTLake StreetMaintains26.0
RAPTPiper SandlerMaintains52.0
OCXLake StreetMaintains6.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com